912773-24-1

Basic information

• Product Name: 6-Bromoimidazo[1,2-a]pyrazine
• Synonyms: 6-BroMoiMidazo[1,2-a]pyra...;6-BroMoiMidazo[1,2-a;6-BroMoidazo[1,2-a]pyrazine;6-BROMOIMIDAZO[1,2-A]PYRAZINE;2-Bromopyrazino[4,5-a]pyrole
• CAS NO: 912773-24-1
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.02
• Product Categories: Fused Ring Systems;Halides;Heterocycles series
• Mol File: 912773-24-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 1.89
• Refractive Index: 1.751
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.60±0.30(Predicted)
• CAS DataBase Reference: 6-Bromoimidazo[1,2-a]pyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromoimidazo[1,2-a]pyrazine(912773-24-1)
• EPA Substance Registry System: 6-Bromoimidazo[1,2-a]pyrazine(912773-24-1)

Safety Data

• Hazardous Substances Data: 912773-24-1(Hazardous Substances Data)

Usage

General Description

6-Bromoimidazo[1,2-a]pyrazine is a chemical compound with the molecular formula C6H4BrN3. It is a heterocyclic aromatic compound that consists of a fused imidazopyrazine ring system with a bromine atom attached at position 6. 6-Bromoimidazo[1,2-a]pyrazine is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active molecules, such as pharmaceuticals and agrochemicals. It is also utilized as an intermediate in the production of materials for electronics, polymers, and other specialty chemicals. 6-Bromoimidazo[1,2-a]pyrazine has potential applications in the development of new drugs and materials due to its unique structure and reactivity.

InChI:InChI=1/C6H4BrN3/c7-5-4-10-2-1-8-6(10)3-9-5/h1-4H

Upstream product

• 59489-71-3 5-amino-2-bromopyrazine 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 107-20-0 2-chloroethanal 
• 17157-48-1 bromoacetaldehyde 

Downstream Products

• 1239441-36-1 3-chloro-6-bromoimidazo[1,2-a]pyrazine 
• 1245644-42-1 6-bromo-3-iodo-imidazo[1,2-a]pyrazine 
• 1426845-50-2 6-bromo-3-(4-fluorophenyl)imidazo[1,2-a]pyrazine 
• 1426845-10-4 2-(4-fluorophenyl)-5-(3-(4-fluorophenyl)imidazo[1,2-a]pyrazin-6-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 

Relevant articles and documents

Imidazopyrazine derivative and synthesis method and application thereof

The invention discloses 6-(6 substituent group-5-sulfonamido-3-pyridine) imidazo [1, 2-a] pyrazine derivatives as shown in a formula (I) or pharmaceutically acceptable salts thereof. The invention also discloses application of the 6-(6-substituent-5-sulfo

Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5

The present invention relates to compounds assumed to be capable of modulating the activity of the proteins ScyI1 and Grk5, thereby regulating the expression and/or release of insulin as well as to pharmaceutical compositions containing such compounds and the use thereof especially for the treatment of a metabolic disease such as diabetes, obesity and impaired adipogenesis.

Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors

Crystal structures of several urea- and thiourea-derived compounds in complex with the nicotinamide phosphoribosyltransferase (Nampt) protein were utilized to design a potent amide-containing inhibitor bearing an aza-indole moiety (7, Nampt BC IC50 = 9.0 nM, A2780 cell proliferation IC 50 = 10 nM). The Nampt-7 cocrystal structure was subsequently obtained and enabled the design of additional amide-containing inhibitors which incorporated various other fused 6,5-heterocyclic moieties and biaryl sulfone or sulfonamide motifs. Additional modifications of these molecules afforded many potent biaryl sulfone-containing Nampt inhibitors which also exhibited favorable in vitro ADME properties (microsomal and hepatocyte stability, MDCK permeability, plasma protein binding). An optimized compound (58) was a potent inhibitor of multiple cancer cell lines (IC50 10 nM vs U251, HT1080, PC3, MiaPaCa2, and HCT116 lines), displayed acceptable mouse PK properties (F = 41%, CL = 52.4 mL/min/kg), and exhibited robust efficacy in a U251 mouse xenograft model.